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248 The Journal of Thoracic and Cardbjective: Although the lung is the most common site of extrahepatic spread from
epatocellular carcinoma, outcomes after pulmonary resection and prognostic fac-
ors have not been well described. We analyzed a single-center experience with 25
atients undergoing pulmonary resection of metastases from hepatocellular carci-
oma to examine the clinical factors and outcomes.
ethods: Patients were candidates for resection if they had controlled intrahepatic
isease with no evidence of extrathoracic lesions and if all gross tumors could be
emoved with preservation of respiratory function. Twenty-five patients with hep-
tocellular carcinoma who underwent curative hepatectomy were suitable for the
ulmonary resection criteria between 1990 and 2005. Clinical features and out-
omes were analyzed.
esults: The mean actuarial 1-, 3-, and 5-year survivals after pulmonary resection
ere 80%, 61%, and 36%, respectively. Tumor number (solitary or multiple) and
ocation (unilateral or bilateral lung) did not significantly affect cancer-specific
urvival. Mean 5-year survival was 25% for patients with disease-free interval of 1
o 11 months and 62% for those with disease-free interval of 12 months or more.
ean survival was 15.9 months for patients with alpha-fetoprotein of 500 ng/mL or
ore, and 39.2 months for those with alpha-fetoprotein less than 500 ng/mL.
ive-year survival was 21% for patients with short disease-free interval or high
lpha-fetoprotein level and 74% for those with long disease-free interval and low
lpha-fetoprotein level (P  .015).
onclusion: Pulmonary resection for metastases from hepatocellular carcinoma
ay prolong survival in selected patients. Disease-free interval greater than 12
onths and alpha-fetoprotein less than 500 ng/mL are important prognostic
actors.
epatocellular carcinoma (HCC) is a highly fatal cancer. It is common in
Japan,1 and its incidence in the United States,2 Europe,3 and the rest of t
world is increasing. Recent progress in the diagnosis and treatment of HCC
as improved patient outcomes. Advances in surgical techniques and perioperative
anagement have reduced the operative morbidity and mortality of patients with
CC. However, the long-term outcome of patients with HCC remains poor because
f a high incidence of recurrence after hepatic resection. The most frequent organ
n which HCC recurs is the liver; the lung is the most common site of extrahepatic
pread.4
Although several case reports5-7 and small studies8-10 have been published in t
nglish-language literature about surgical resection of pulmonary metastases from
CC, the indications for these procedures and the prognostic factors have not yet
een standardized. We reviewed our experience with surgical treatment of pulmo-
ary metastases from HCC to analyze the clinical factors and outcome.
iovascular Surgery ● June 2006
M
B
H
G
d
g
a
t
b
i
e
m
c
l
c
d
w
d
c
l
i
o
P
S
t
t
S
T
b
c
t
c
a
r
t
o
f
I
R
T
n
f
d
t  had
s
t
p
b
T
t
e
t
h
t
r
i
c
n
t
p
u
u
p
o
l
p
o
n
r
T
m
a
a nts
(
fi
m
m
w
i
m
r
l
m
w
(
3
o
l
a
i
Nakagawa et al General Thoracic Surgery
G
TSethods
etween January 1987 and December 2003, 544 patients with
CC underwent curative partial hepatectomy in the Department of
eneral Surgery, Hokkaido University Hospital. Twelve patients
ied in the hospital. The remaining 532 were followed after sur-
ery at the outpatient clinic at intervals of 3 months with serum
lpha-fetoprotein (AFP) measurements and abdominal computed
omography (CT) scans. Pulmonary recurrence was also checked
y chest radiograph, and chest CT was performed when AFP was
ncreased or recurrence was suspected.
Selection criteria for pulmonary resection were as follows: no
vidence of uncontrollable intrahepatic disease, no evidence of
etastatic disease at another site, and CT demonstrating that
omplete resection could be performed regardless of the number of
esions. Tumors in the bilateral thorax were not considered to be a
ontraindication. In patients in whom additional lung metastases
eveloped after resection, further resection was performed if there
as no other visceral recurrence. Patients with uncontrolled liver
isease or unresectable multiple lung metastases were offered
hemotherapy.
Principally, wedge resection was the procedure of choice, and
ymph node dissection was not undertaken.
Data on patients’ clinical characteristics, serum AFP level
mmediately before pulmonary resection, operative findings, and
perative outcomes were obtained from the Hepatobiliary and
ancreatic Service Database of the Department of General
urgery.
The disease-free interval (DFI) comprised the period between
he last curative treatment for intrahepatic disease and the detec-
ion of pulmonary deposits.
tatistics
he chi-square test was used to compare categoric variables
etween the 2 groups. The unpaired t test was used to
ompare continuous variables. Survival was estimated by
he Kaplan-Meier method, and differences between survival
urves were tested by the log-rank test. Overall survival
fter pulmonary resection was calculated using data on all
esected patients. For analysis of clinical factors related to
he pulmonary tumor, 1 patient who died in the early post-
perative period was excluded. Statistical analysis was per-
ormed using StatView for Windows (Version 5.0, SAS
nstitute Inc, Cary, NC).
esults
wenty-five patients were suitable in the criteria of pulmo-
Abbreviations and Acronyms
AFP  alpha-fetoprotein
CT  computed tomography
DFI  disease-free interval
HCC  hepatocellular carcinoma
TACE transcatheter arterial chemoembolizationary resection, and curative pulmonary resection was per- t
The Journal of Thoracicormed in all of them between 1990 and 2005. The clinical
etails of the 25 patients who underwent pulmonary resec-
ion are summarized in Table 1. All patients but 1
olitary or resectable multiple lung tumors without uncon-
rolled hepatic disease. One patient (case 1) had multiple
ulmonary metastases that were treated with systemic and
ronchial arterial infusion chemotherapy for 26 months.
he chemotherapy reduced his multiple tumors to 2, but
hese 2 tumors persisted and began to enlarge again. How-
ver, this patient had become eligible for pulmonary resec-
ion after effective chemotherapy.
Eight patients (cases 2, 4, 5, 8, 14, 22, 23, and 24) had
epatic recurrence before the discovery of pulmonary metas-
ases. All hepatic recurrences had been treated successfully by
e-hepatectomy (cases 4, 14, 22, and 24), percutaneous ethanol
njection therapy (cases 2, 4, and 8), transcatheter arterial
hemoembolization (TACE) (cases 5 and 23), and/or percuta-
eous radiofrequency ablation therapy (case 22).
Wedge resection was performed in 21 patients, lobec-
omy in 2 patients, lobectomy plus wedge resection in 1
atient, and bilateral lobectomy in 1 patient. Six patients
nderwent a second pulmonary resection, and 1 patient
nderwent a third pulmonary resection. Altogether, the 25
atients underwent 32 pulmonary resections. There was 1
perative death as the result of pyothorax 19 days after a
obectomy, giving an operative mortality rate of 3.1%. Ten
atients died of HCC recurrence. One patient (case 9) died
f sepsis 59 months after pulmonary resection, but he had
o evidence of HCC involvement at death.
The median follow-up for patients after pulmonary
esection was 37.3 months (range, 0.6-177.4 months).
he median survival after pulmonary resection was 51.8
onths. The actuarial overall 1-, 3-, and 5-year survivals
fter pulmonary resection were 80%  8%, 61%  10%,
nd 36%  13%, respectively (Figure 1). Three patie
cases 1, 3, and 11) have survived more than 5 years. The
rst patient (case 1), who had the bilateral residual tu-
ors after chemotherapy, underwent right upper and
iddle lobectomy and left lower lobectomy; he is alive
ith no recurrence at 177 months. Two tumors developed
n the second patient’s right lung after a DFI of 22
onths (case 3); these were removed with a wedge
esection. Subsequently, 2 masses developed in the left
ung, necessitating a second partial lung resection at 10
onths after the first. This patient is alive at 142 months
ith no evidence of recurrent disease. The third patient
case 11) underwent partial lung resection 3 times at 27,
3, and 45 months after right hepatectomy. The first
peration involved wedge resections for a tumor in the
eft lung and another in the right lung; the second was for
nodule in the right lung, and the third was for a tumor
n the left lung. A new liver tumor appeared 2 years after
he third pulmonary resection, but the liver disease was
and Cardiovascular Surgery ● Volume 131, Number 6 1249
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G
TSell controlled by TACE. He is alive at 68 months after
he first pulmonary resection and remains disease-free at
5 months after TACE.
In the 24 patients who survived the immediate postopera-
ive period, neither tumor number (solitary or multiple) nor
umor distribution (unilateral or bilateral lung) had a significant
ffect on survival (Table 2). The mean DFI was 16.3 m
range, 1-37 months). Ten patients had a DFI of 1 to 11
onths, and 14 patients had a DFI of 12 months or more.
hen cancer-specific survival was analyzed according to
ength of DFI, the mean survival was 30.6 months for patients
ho were disease-free for less than 12 months versus 35.4
onths for those who remained disease-free for 12 months or
ore (P  .117) (Figure 2, A).
Nineteen patients had serum AFP levels of less than 500
g/mL; mean survival among these patients was 39.2 months.
n the 5 patients with AFP levels of 500 ng/mL or more, mean
urvival was 15.9 months (P  .225) (Figure 2, B).
Patients were then divided into 2 groups according to
ABLE 1. Clinical details and surgical results of patient
epatocellular carcinoma
atient
o. Sex Age (yr) HBsAg/HCV-Ab
1 M 32 /n.a. H
2 M 54 /n.a. H
3 M 42 / H
4 M 43 / H
5 M 61 / H
6 M 54 / H
7 M 37 / H
8 M 68 / H
9 M 69 / H
0 M 64 / H
1 M 61 / H
2 M 71 / H
3 M 61 / H
4 M 68 / H
5 M 46 / H
6 M 74 / H
7 M 49 / H
8 M 50 / H
9 F 75 / H
0 M 75 / H
1 M 60 / H
2 M 40 / H
3 M 73 / H
4 M 53 / H
5 F 51 / H
x, hepatic resection; n.a., not available; PEIT, percutaneous ethanol injec
hemoembolization. *Recurrence organs at the follow-up end-point or to d
ecurrence disease was uncontrolled or disseminated.FI and AFP levels. Group I patients (low-risk group, n  m
250 The Journal of Thoracic and Cardiovascular Surgery ● Juns
igure 1. Overall survival in patients who underwent curative pul-s who underwent pulmonary resection for metastases from
Hepatic
treatment
Disease-free
survival (mos)
Pulmonary
tumor
number
Pulmonary
tumor
location
x 7 2 Bilateral
x, PEIT 16 1 Unilateral
x 22 2 Unilateral
x, Hx, PEIT 1 4 Bilateral
x, TACE 4 1 Unilateral
x 21 2 Unilateral
x 2 3 Bilateral
x, PEIT 22 3 Unilateral
x 26 5 Unilateral
x 16 6 Bilateral
x 26 2 Bilateral
x 33 1 Unilateral
x 10 1 Unilateral
x, Hx 23 1 Unilateral
x 4 1 Unilateral
x 13 4 Unilateral
x 4 1 Unilateral
x 6 14 Bilateral
x 34 1 Unilateral
x 29 3 Bilateral
x 6 4 Bilateral
x, Hx, RFA 7 1 Unilateral
x, TACE 37 1 Unilateral
x, Hx 26 1 Unilateral
x 13 2 Unilateral
tion therapy; RFA, radiofrequency ablation therapy; TACE, transcatheter arterial
eath, †Resected, Œ; Recurrence disease was resected or well-controlled, ;onary metastasectomy from hepatocellular carcinoma (n  25).
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TS2) had DFIs of 12 months or more and AFP levels less than
00 ng/mL. Group II patients (high-risk group, n  12) had
FIs less than 12 months or AFP levels of 500 ng/mL or
erum AFP
level (ng/
mL)
Repulmonary
resection
(times)
Survival
(mos) Outcome
3.5 177 Alive
1433.7 19 days Dead, pyothorax
432 1 142 Alive
6.2 51 Dead
484 6 Dead
599.7 21 Dead
12.6 3 Dead
17.6 16 Dead
366 1 59 Dead, free from
6.1 1 42 Dead
169 2 68 Alive
6.9 59 Alive
2260 6 Dead
34.5 1 51 Alive
484 17 Dead
1.3 34 Alive
5.8 38 Alive
1181 1 29 Alive
97 26 Alive
2341 8 Dead
663 22 Alive
30.1 13 Dead
2.9 14 Alive
1.6 11 Alive
3 7 Alive
ABLE 2. Kaplan-Meier analysis of cancer-specific surviv
actor n 1-year survival, %
umor number
Single 10 80
Multiple 14 85
umor location
Unilateral 16 88
Bilateral 8 75
isease-free survival
Under 12 mos 10 70
Over 12 mos 14 92
erum AFP level
(ng/ml)
500 19 90
500 5 60
The Journal of Thoracicore. Overall survivals at 3 and 5 years were 89%  11%
nd 74%  16%, respectively, for group I patients and 42%
14% and 21%  16%, respectively, for group II patients
Recurrence site after pulmonary resection*
Liver Lung Others
Œ
 

Brain
 Adrenal gland

Œ
 Œ
Œ, Œ
Œ Adrenal gland†, Bone
Brain
Œ Œ
 Mediastinal lymph nodes
 
Abdominal peritoneum
 , Œ Mediastinal lymph nodes, Bone
Mediastinal lymph nodes,
Carcinomatosa pleulitis

 Mediastinal lymph nodes, Brain
Value, Log Rank)
3-year survival, % 5-year survival, % P Value
55 — 0.683
70 46
56 56 0.918
75 38
50 25 0.117
74 62
71 52 0.225S
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TSP  .015) (Figure 3). The number of patients who 
ecurrence after pulmonary metastasectomy is shown in
able 3. The incidences of intrahepatic recurrence and 
onary re-recurrence did not differ between the low- and
igh-risk groups. Five of 6 low-risk patients who had pul-
onary re-recurrence required further resection. In all 5
igh-risk patients with pulmonary re-recurrence, however,
ulmonary involvement was disseminated. The incidence of
etastases to other organs was significantly higher in the
igh-risk group than in the low-risk group (P  .003,
hi-square test).
iscussion
dvances in surgical techniques and perioperative manage-
ent have resulted in better outcomes and lower operative
ortality rates in patients with HCC in recent years.4 Still,
he recurrence rate after curative resection of HCC is high,
ith distant metastasis most frequently found in the lu4
n our experience, only a few cases were suitable for sur-
ical resection.
The few English-language reports on pulmonary resec-
ion of metastases from HCC are summarized in Tab
am and colleagues8 described 9 cases of pulmonary rese-
ion. Their 5-year survival of 67% is better than our rate of
6%, but their patients had solitary metastases and long
FIs. They did not perform resections on patients with
ultiple lung metastases. In a series reported by Chen and
olleagues,10 5 of 6 patients had multiple pulmon
etastases.
Rusch11 asserted in a review article that the objectiv
esection of pulmonary metastases is to remove all gross
umor while preserving as much normal pulmonary paren-
hyma as possible. We considered patients to be candidates
or curative resection as long as their respiratory function
ould be preserved. In fact, we found no significant differ-
nce in survival between patients with solitary tumors and
atients with multiple tumors. Three patients in our series
re still alive more than 5 years after pulmonary resection. l
252 The Journal of Thoracic and Cardiovascular Surgery ● Jun.
ach had 2 pulmonary metastatic tumors. Thus, our expe-
ience suggests that curative resection might allow a good
rognosis even in patients with multiple pulmonary
etastases.
In our series, DFI was an important prognostic fac-
or.12,13 Some authors have reported that a DFI more 
6 months is a good prognostic factor in colorectal can14
r breast cancer.15 Those authors calculated the DFI 
tarting at the surgical resection of the primary tumor,
hereas we considered it to begin at the last curative treat-
ent for intrahepatic disease. We defined the DFI in this
ay because patients were often treated for intrahepatic
CC recurrence several times before distant metastases
ppeared.
Figure 2. Cancer-specific survival in patients
with pulmonary metastasectomy. A, Accord-
ing to the DFI: >12 months (n  14) (solid
line), <12 months (n  10) (dotted line). B,
According to the serum AFP level at pre-
pulmonary resection: <500 ng/mL (n  19)
(solid line); >500 ng/mL (n  5) (dotted line).
igure 3. Cancer-specific survival related to the DFI and serum
FP level at pre-pulmonary resection. Low-risk group (solid line):
FI >12 months and AFP <500 ng/mL (n  12). High-risk group
dotted line): DFI <12 months and AFP >500 ng/mL (n  12);
og-rank test: P  .015
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Hx, hepatic resection; TACE, transcatheter arterial chemoembolization; St, solit
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G
TSIn an analysis of patients with pulmonary metastases
rom colorectal cancer, carcinoembryonic antigen level
as a significant prognostic factor; patients were divided
nto 2 groups according to whether their carcinoembry-
nic antigen levels were normal or elevated (5 ng/
L).14 In a study of patients with HCC with prim
esions, the Cancer of the Liver Italian Program investi-
ators16 developed a scoring system that included as 
ts components an AFP level greater than or less than 400
g/dL. Hanazaki and colleagues17 reported that serum
FP level was a significant prognostic factor after he-
atic resection of hepatitis C virus-related primary HCC.
n their study, the cutoff value of AFP was 1000 ng/mL.
s in other studies, serum AFP level before pulmonary
etastasectomy was a prognostic factor in our study. We
ound 500 ng/mL to be the cutoff value that in combina-
ion with DFI could separate high- and low-risk groups
f hepatocellular carcinoma
number St : Mt
Disease-free
interval,
month, mean
(range)
Median survival
after pulmonary
resection
(longest
survivor)
5-year survival
rate
9:0 21.8 (10-51) 42 mos 67%
(127 mos
alive)
3:1 10.3 (0-35) Not described Not described
(72 mos alive)
1:5 27.8 (10-75) 47 mos (mean
survival)
Not described
(94 mos
alive)
10:14 16.3 (1-37) 52 mos 36%
(177 mos
alive)ABLE 3. Comparison of recurrence cases after pulmonary
esection among low and high risk groups (P Value, Chi
quare test)
ecurrence site
Low risk group
(n  12)
High risk group
(n  12) P Value
iver
Absent 6 8 0.408
Present 6 4
ung
Absent 6 7 0.682
Present 6 5
thers
Absent 11 4 0.003
Present 1 8ABLE 4. Summary of studies for pulmonary metastasectomy o
tudy and
ocation Patients number
Criteria for pulmonary
resection Tumor
am et al.8
1998
9 post-Hx 1. Solitary pulmonary
tumor
ong Kong 2. Without concurrent
intrahepatic
recurrence
wak et al.9
2004
2 post-Hx and 1. Without concurrent
intrahepatic
recurrence
epublic of
Korea
2 post-TACE 2. The metastatic lesions
appeared to be
amenable to complete
resection
3. No evidence of
metastatic disease at
another site
hen et al.10
2004
6 post-Hx Without concurrent
intrahepatic recurrence
aiwan
ur series 25 post-Hx 1. No evidence of
uncontrollable
intrahepatic disease
2. No evidence of
metastatic disease at
another site
3. Complete resection
could be performed
regardless of the
number or the lesionsary; Mt, multiple.
and Cardiovascular Surgery ● Volume 131, Number 6 1253
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TSith statistical significance. In living-donor liver trans-
lantation for adult patients with HCC, pretransplant
erum AFP level is significantly associated with patient
urvival on univariate analysis and independent risk fac-
ors by multivariate analysis.18 Poor tumor cell differen-
iation is a poor prognostic factor, and serum AFP level
s related to HCC cell differentiation.19 A high AFP leve
s a poor prognostic factor not only in the metastatic stage
ut also in several clinical features.
Although neither DFI nor AFP level alone was a
tatistically significant prognostic factor, survival in
roups divided according to a combination of these pa-
ameters was significantly different. Patients with short
FIs or high AFP levels had a high incidence of dissem-
nated pulmonary reappearance and distant metastases. In
hese high-risk patients, even when it seems that curative
esection of pulmonary metastases is possible, it is likely
hat occult metastases are present and their disease is
idespread.
onclusion
ur investigation showed that a DFI of more than 1 year
nd a serum AFP level less than 500 ng/mL together predict
better outcome after pulmonary metastasectomy of HCC,
ith 3- and 5-year survivals of 89% and 74%, respectively.
ggressive surgical management of resectable pulmonary
etastases from HCC is justified in selected patients.
The authors thank the staff of the First Department of Surgery,
okkaido University Medical Hospital for their clinical assistance,
nd Ms Nancy Ehrlich Lapid for editorial assistance.
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